Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PledOx for Prevention of Oxaliplatin-Induced Neuropathy in mCRC
NCT03654729Phase 3Terminated
- Sponsor
- Egetis Therapeutics
- Start
- Nov 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of calmangafodipir in chemotherapy-induced peripheral neuropathy (CIPN) (3 arms), sponsored by Egetis Therapeutics. Primary endpoint: Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy at 9 months. Started Nov 2018; status: terminated.
02
Drugs
calmangafodipir
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT03654729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654729.